Search the Newsreel

Mangoceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Mangoceuticals, Inc. announced its earnings for the second quarter and six months ending June 30, 2026. For the second quarter, sales were USD 0.068757 million with a net loss of USD 1.31 million. Over the six-month period, sales totaled USD 0.136621 million, resulting in …

Nuclea’s planned Moltex deal could add 80 nuclear patents

Mangoceuticals' merger partner, Nuclea Energy, Inc., has entered into a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy, which is currently in administration. The acquisition includes intellectual property for Moltex’s SSR‑W advanced molten salt reactor, WATSS spent-fuel recycling process, and the …

Mangoceuticals (MGRX) Q2 2026 loss shrinks while cash and revenue fall

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Mangoceuticals Inc.'s merger partner, Nuclea Energy, Inc., has entered into a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy Limited. This acquisition includes Moltex's Stable Salt Reactor–Wasteburner (SSR-W) and Waste To Stable Salt (WATSS) spent nuclear fuel recycling process, along with …

12 Consumer Staples Stocks Moving In Thursday's After-Market Session

This article lists consumer staples stocks that experienced significant movement in Thursday's after-market session. It details both gainers, such as Mangoceuticals and Laird Superfood, and losers, including Branchout Food and Planet Green Holdings, along with their respective percentage changes and market caps.

Mangoceuticals (MGRX) Earnings Date and Reports 2026

Mangoceuticals, Inc. (MGRX) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Mangoceuticals, Inc. (MGRX) stock, including its current price, historical data, financial metrics, and company profile. MGRX is engaged in the development and sale of men's wellness products through a telemedicine platform, offering brands like Mango, …

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU With New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Nuclea Energy Inc., a merger partner of Mangoceuticals, has signed a Memorandum of Understanding with New Mining Co. to collaborate on the deployment of behind-the-meter modular reactors for high-density computing infrastructure. This partnership aims to provide reliable, carbon-free, and cost-effective power solutions for data …

Bitcoin miner explores modular reactors for up to 100 MWe

Mangoceuticals announced that its merger partner, Nuclea Energy Inc., signed a non-binding MOU with New Mining Co. to assess the deployment of Nuclea's modular reactor technology for New Mining's high-density computing and Bitcoin mining operations. The evaluation will proceed in phases, starting with engineering …

Mangoceuticals (MGRX) merger partner Nuclea inks Utah nuclear test reactor MOU

Mangoceuticals, Inc. announced that its merger partner's subsidiary, Nuclea Energy USA Inc., signed a memorandum of understanding (MOU) with the Utah Office of Energy Development. This MOU aims to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab to advance …

Why is Mangoceuticals stock surging today?

Mangoceuticals (MGRX) stock surged over 31% in pre-open trading after its merger partner, Nuclea Energy Inc., announced a key regulatory milestone for its Morpheus microreactor program. This development involves a memorandum of understanding to explore siting a nuclear test reactor in Utah, bolstering investor …

Mangoceuticals Wins Nasdaq Extension Amid Nuclea Deal Progress

Mangoceuticals (MGRX) has received a second 180-day extension from Nasdaq, pushing its compliance deadline to February 1, 2027, to restore its stock price above $1.00. This extension provides flexibility as the company advances a definitive business combination agreement with Nuclea Energy Inc., an advanced …

Utah Lab and Nuclea Explore Morpheus Test-Reactor Site

Mangoceuticals' merger partner, Nuclea Energy USA, has signed a Memorandum of Understanding (MOU) with the Utah Office of Energy Development to explore siting a nuclear test reactor for its Morpheus microreactor at the Utah San Rafael Energy Lab. This agreement is a significant step …

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why

Mangoceuticals (MGRX) stock surged over 49% after hours following news that its merger partner, Nuclea Energy Inc., through its subsidiary Nuclea Energy USA Inc., signed a memorandum of understanding with Utah's Office of Energy Development. This MOU explores siting a nuclear test reactor for …

Wondering what's happening in today's after-hours session?

This article provides an overview of the top gainers and losers in the US after-hours trading session on Wednesday, August 5, 2026. It highlights several companies, including MANGOCEUTICALS INC (MGRX) and CREATIVE MEDICAL TECHNOLOGY (CELZ) as top gainers, and YXT.COM GROUP HOLDING LTD (YXT) …

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Mangoceuticals' merger partner, Nuclea Energy, has signed a Memorandum of Understanding (MOU) with the Utah Office of Energy Development to explore siting a nuclear test reactor for its Morpheus microreactor at the Utah San Rafael Energy Lab. This partnership aims to advance the research, …

Mangoceuticals Has Until Feb. 1, 2027 to Meet Nasdaq's $1 Bid Rule

Mangoceuticals (NASDAQ: MGRX) has received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, setting a new deadline of February 1, 2027. The company may consider a reverse stock split if necessary to meet the requirement, which involves …

Mangoceuticals Granted 180-Day Extension by Nasdaq to

Mangoceuticals Inc. (NASDAQ: MGRX) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to February 1, 2027. The company is simultaneously advancing its business combination with Nuclea Energy Inc., which is developing the Morpheus …

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

Mangoceuticals Inc. (NASDAQ: MGRX) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to February 1, 2027. The company is simultaneously advancing its business combination with Nuclea Energy Inc., which is developing the Morpheus …

Mangoceuticals (NASDAQ: MGRX) wins more time on Nasdaq rules, advances Nuclea deal

Mangoceuticals (NASDAQ: MGRX) has secured an additional 180-day extension from Nasdaq to meet the minimum bid price requirement, pushing the deadline to February 1, 2027. This extension provides the company flexibility as it progresses with a definitive business combination agreement with Nuclea Energy Inc., …

Mangoceuticals, Inc. Common Stock (NASDAQ: MGRX) Stock Price, News & Analysis

$Mangoceuticals (MGRX.US)$

The article is a single comment from a user named "Darnelle Taught Me" on the moomoo community feed, referencing Mangoceuticals (MGRX.US). It appears to be a user-generated post within a financial social media platform, with a disclaimer about educational purposes.

MGRX surges after Nuclea Energy reverse-merger deal reshapes company story

Mangoceuticals, Inc. (MGRX) stock surged 172.5% today following its definitive business combination agreement with Nuclea Energy. This reverse-merger transforms MGRX from a telehealth company into a speculative nuclear-power listing, attracting significant investor interest. Nuclea Energy, a developer of advanced nuclear technology, is expected to …

$Mangoceuticals (MGRX.US)$ sold a tad early. but definitely looking for another entry!

A moomoo Community user, MsNoFomoTrade, commented on the stock $Mangoceuticals (MGRX.US), stating they sold their shares a bit prematurely but are actively seeking another entry point. The post indicates investor interest in re-engaging with the stock despite a previous early exit.

Mangoceuticals agrees to merge with nuclear microreactor developer By Investing.com

Mangoceuticals, Inc. (NASDAQ:MGRX) has announced a definitive merger agreement with Nuclea Energy Inc., a nuclear technology company developing the Morpheus microreactor. Under the terms, Nuclea will become an indirect wholly owned subsidiary of Mangoceuticals, with Nuclea shareholders receiving exchangeable shares in Mangoceuticals. The transaction, …

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

Nuclea Energy Inc. has entered into a definitive business combination agreement with Mangoceuticals, Inc. to gain a Nasdaq public listing, aiming to fund the development and commercialization of its Morpheus microreactor. This move positions Nuclea to capitalize on the increasing demand for continuous, carbon-free …

Mangoceuticals (MGRX) plans merger giving Nuclea Energy 96% post-close stake

Mangoceuticals, Inc. (MGRX) has entered a definitive business combination agreement with Nuclea Energy Inc., where a newly formed Mangoceuticals subsidiary will amalgamate with Nuclea. This merger is intended to provide Nuclea a pathway to a Nasdaq public listing and significant capital access for developing …

Mangoceuticals Reports Merger Deal With Nuclea Energy

Mangoceuticals (MGRX) plans Nuclea merger, 96% new-owner stake, $15M PIPE

Mangoceuticals (MGRX) has announced a Business Combination Agreement with Nuclea Energy Inc. through which Nuclea shareholders will own approximately 96% of the combined entity on a fully diluted basis before PIPE financing, with existing Mangoceuticals stockholders retaining about 4%. The transaction involves a two-stage …

Mangoceuticals to Combine With Nuclea Energy; Nuclea Holders to Own ~96% Pre-PIPE

Mangoceuticals (MGRX) has entered into a Business Combination Agreement with Nuclea Energy, utilizing a Canadian exchangeable-share structure. Upon closing, Nuclea shareholders will receive exchangeable shares in a Mango subsidiary, which can be exchanged for Mango common stock. Former Nuclea holders are expected to own …

Mangoceuticals Deal Would Put Nuclea's ~3.5-50 MWe Reactor on Nasdaq Path

Mangoceuticals (NASDAQ: MGRX) has signed a definitive business combination agreement with Nuclea Energy, a Canadian developer of the lead-cooled Morpheus microreactor, to advance next-generation nuclear microreactor technology. The deal is structured to provide Nuclea a Nasdaq listing and offer Mangoceuticals shareholders exposure to the …

Jacob D. Cohen to Leave CEO Role at Mangoceuticals, Becomes President in Consulting Role

Jacob D. Cohen, CEO of Mangoceuticals (MGRX), will step down from his CEO role upon the closing of a transaction, transitioning instead to President in an independent consulting capacity. New executive officers will be appointed by the Principal Nuclea Shareholders, and existing executives not …

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals, Inc. (NASDAQ: MGRX) has announced a definitive business combination agreement with Nuclea Energy Inc., a developer of advanced nuclear microreactor technology. This reverse merger will allow Nuclea to access public markets, aiming to capitalize on the increasing demand for continuous, carbon-free power driven …